Fibromodulin peptide

Abstract

Disclosed herein is a method of making a fibromodulin peptide (FMOD-P), compositions thereof, and methods of using the FMOD-P and the compositions thereof for treating or ameliorating a condition.

We claim: 
     
         1 . A method of making an isolated fibromodulin (FMOD) peptide (FMOD-P), comprising:
 designing a FMOD-P having the function to bind at least one beta-tissue growth factor (TGF-β), and   preparing the FMOD-P, wherein FMOD-P is an isoform of a full length FMOD and has consists of an amino acid sequence up to 91 amino acids in length.   
     
     
         2 . The method of  claim 1 , wherein the FMOD-P consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 6 0, SEQ ID NO: 61, SEQ ID NO: 62, and SEQ ID NO: 63. 
     
     
         3 . The method of  claim 1 , wherein preparing comprises splicing FMOD at one or more selected sites to generate the FMOD-P. 
     
     
         4 . The method of  claim 1 , wherein preparing comprises:
 expressing the isolated FMOD-P in a recombinant system; or   producing the isolated FMOD-P in a cell free translation system.   
     
     
         5 . The method of  claim 1 , wherein preparing comprises expressing the isolated FMOD-P in a bacterial, yeast, mammalian, or plant cell. 
     
     
         6 . The method of  claim 1 , wherein designing is achieved by hydrophobic analysis of a primary or secondary structure of FMOD. 
     
     
         7 . A method, comprising:
 providing an ingredient selected from any of the following:
 a) an isolated FMOD-P; 
 b) a combination of isolated FMOD-P; 
 c) an isolated FMOD-P or a combination of isolated FMOD-P and at least one TGF-β isoform; 
 d) isolated FMOD and an isolated FMOD-P or a combination of isolated FMOD-P; and 
 e) any combination of a)-(d), 
   forming a composition comprising any of ingredients a)-(e),   wherein FMOD-P is an isoform of a full length FMOD and consists of an amino acid sequence up to 91 amino acids in length,   wherein the at least one TGF-β isoform is selected from the group consisting of TGF-β1, TGF-β2, TGF-β3, and a combination thereof, and   wherein the FMOD-P is capable of binding to at least one TGF-β isoform.   
     
     
         8 . The method of  claim 7 , wherein forming further comprises:
 providing an excipient, and   forming a formulation comprising the ingredient and the excipient.   
     
     
         9 . The method of  claim 7 , wherein the FMOD-P consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 6 0, SEQ ID NO: 61, SEQ ID NO: 62, and SEQ ID NO: 63. 
     
     
         10 . The method of  claim 7 , wherein the FMOD consists of an amino acid sequence selected from the group consisting of SEQ ID NO. 1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, SEQ ID NO. 10, SEQ ID NO. 11, and SEQ ID NO. 12. 
     
     
         11 . A method for treating, preventing, or ameliorating a body condition, comprising administering a composition to a subject, wherein the composition comprises an effective amount of any of the following ingredients:
 a) an isolated FMOD-P;   b) a combination of isolated FMOD-P;   c) an isolated FMOD-P or a combination of isolated FMOD-P and at least one TGF-β isoform;   d) isolated FMOD and an isolated FMOD-P or a combination of isolated FMOD-P; and   e) any combination of (a)-(d),   wherein FMOD-P is an isoform of a full length FMOD and consists of an amino acid sequence up to 91 amino acids in length,   wherein FMOD-P is an isoform of FMOD having a shorter amino acid sequence than that of FMOD, wherein the at least one TGF-β isoform is selected from the group consisting of TGF-β1, TGF-β2, TGF-β3, and a combination thereof, wherein the FMOD-P is capable of binding to at least one TGF-β isoform, and   wherein the composition is suitable for systemic or local delivery and comprises the composition and an excipient.   
     
     
         12 . The method of  claim 11 , wherein the body condition is selected from the group consisting of excessive fibrosis or scar formation that are associated with high TGF-β expression, hypertrophic scars, keloids, radiation fibrosis, and fibrotic conditions in organ systems other than skin. 
     
     
         13 . The method of  claim 11 , wherein the body condition is pulmonary fibrosis or a liver, kidney, cornea, intra-abdominal, gastrointestinal, urological, neurological, or cardiovascular condition. 
     
     
         14 . The method of  claim 11 , wherein the FMOD-P consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 6 0, SEQ ID NO: 61, SEQ ID NO: 62, and SEQ ID NO: 63. 
     
     
         15 . The method of  claim 11 , wherein the FMOD consists of an amino acid sequence selected from the group consisting of SEQ ID NO. 1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, SEQ ID NO. 10, SEQ ID NO. 11, and SEQ ID NO. 12.